Production (Stage)
Candel Therapeutics, Inc.
CADL
$5.01
-$0.15-2.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 189.76% | -26.84% | -26.21% | -131.30% | 6.53% |
| Total Depreciation and Amortization | -2.39% | -1.61% | 0.00% | 5.51% | 9.13% |
| Total Amortization of Deferred Charges | -46.99% | -39.53% | -25.30% | -7.59% | 10.67% |
| Total Other Non-Cash Items | -1,378.43% | 314.65% | 718.49% | 2,169.84% | 581.33% |
| Change in Net Operating Assets | -8.50% | -53.48% | 179.77% | -69.18% | 32.59% |
| Cash from Operations | -2.11% | 21.67% | 25.37% | 13.86% | 22.01% |
| Capital Expenditure | 57.14% | 93.62% | 100.00% | 96.45% | 94.93% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 57.14% | 88.89% | 100.00% | 96.45% | -136.84% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -49.97% | -- | -- | -- | -- |
| Issuance of Common Stock | 52.91% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -49.00% | 76,061.16% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -8.13% | 1,237.33% | 45.06% | 42.16% | 10.19% |